Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Lixiana

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links